Phospho-PRKCZ (Thr560) Antibody

What epitope does Phospho-PRKCZ (Thr560) antibody specifically recognize?

Phospho-PRKCZ (Thr560) antibody specifically recognizes Protein Kinase C Zeta Type (PRKCZ) only when phosphorylated at Threonine 560. The antibody is typically raised against a synthesized peptide derived from human PKC zeta around the phosphorylation site of Thr560, specifically at the amino acid range of 526-575. The exact immunogen sequence used by some manufacturers consists of the peptide sequence Q-L-T(p)-P-D, where T(p) represents the phosphorylated threonine . This specificity ensures that the antibody does not cross-react with unphosphorylated PRKCZ or with other phosphorylation sites.

What applications are Phospho-PRKCZ (Thr560) antibodies validated for?

Phospho-PRKCZ (Thr560) antibodies have been validated for multiple applications with specific recommended dilution ranges:

Researchers should validate these dilutions in their specific experimental systems, as optimal concentrations may vary based on sample type and detection methods .

How should samples be prepared for optimal detection of phosphorylated PRKCZ at Thr560?

For optimal detection of phosphorylated PRKCZ at Thr560, samples should be handled with particular attention to preserving phosphorylation status:

• Tissue samples: Fix tissues rapidly in phosphatase inhibitor-containing buffers before formalin fixation and paraffin embedding. For IHC applications, 10 μm thick sections have been successfully used .

• Cell lysates: Harvest cells directly in ice-cold lysis buffer containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, and beta-glycerophosphate) to prevent dephosphorylation.

• Protein extraction: Maintain samples at 4°C throughout processing and include protease inhibitors alongside phosphatase inhibitors.

• Western blotting: When preparing samples for Western blot, use 5% BSA rather than milk for antibody dilution, as demonstrated in protocols using anti-PKC ζ(phospho-Thr410) antibodies, which follow similar principles to Thr560 detection .

What controls should be included when using Phospho-PRKCZ (Thr560) antibody?

Rigorous experimental design requires appropriate controls to validate Phospho-PRKCZ (Thr560) antibody specificity:

• Positive control: Lysates from cells treated with phorbol 12-myristate 13-acetate (PMA, 125 ng/ml for 30 minutes) can serve as positive controls, as this treatment has been shown to induce PRKCZ phosphorylation .

• Negative control: Include samples where the phosphorylation site is blocked with the phospho-peptide used as the immunogen. This approach has been demonstrated with Western blot analysis of COS7 cells and immunohistochemistry of human brain tissue .

• Knockout control: When available, samples from PRKCZ knockout models (Prkcz -/- mice) provide definitive confirmation of antibody specificity. Studies have shown that true phospho-specific antibodies should show no signal in knockout tissues .

• Dephosphorylation control: Treating a portion of your samples with lambda phosphatase before immunoblotting can confirm phospho-specificity.

What are the recommended storage conditions to maintain antibody activity?

To preserve antibody activity and prevent degradation:

• Store the antibody at -20°C for up to 1 year from the date of receipt.

• Avoid repeated freeze-thaw cycles which can lead to protein denaturation and loss of activity.

• Most Phospho-PRKCZ (Thr560) antibodies are supplied in a formulation containing PBS, 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability during storage .

• Working aliquots can be prepared to minimize freeze-thaw cycles of the stock solution.

• For short-term storage (less than one week), antibodies can be kept at 4°C in appropriate storage buffer.

How can Phospho-PRKCZ (Thr560) antibody be used to investigate PI3K/Akt signaling crosstalk?

Phospho-PRKCZ (Thr560) antibody can be utilized to investigate crosstalk between PRKCZ and PI3K/Akt signaling pathways through several methodological approaches:

• Co-immunoprecipitation studies: Immunoprecipitate phosphorylated PRKCZ using the Thr560 antibody and probe for associated proteins in the PI3K/Akt pathway, or vice versa.

• Dual phosphorylation analysis: Perform dual immunostaining with Phospho-PRKCZ (Thr560) and phospho-Akt antibodies to examine their co-localization and activation patterns in tissues. This approach has been particularly informative in cancer research, where alterations in Akt signaling are well-documented .

• Pharmacological inhibition: Examine the effect of PI3K inhibitors on PRKCZ Thr560 phosphorylation status. Research has shown that PKCζ phosphorylation at Thr-410 (another regulatory site) is inhibited by PI3K inhibitors, suggesting a similar mechanism might apply to Thr560 .

• Mutational analysis: Compare Thr560 phosphorylation in cells expressing wild-type versus mutant PIK3CA. Recent research has linked oncogenic PIK3CA with enhanced arachidonic acid production through PKCζ activity, indicating a functional relationship between these pathways .

What is the significance of detecting Thr560 phosphorylation versus Thr410 phosphorylation in PRKCZ?

The detection of phosphorylation at different sites provides insight into distinct regulatory mechanisms of PRKCZ:

• Activation mechanism: Thr410 phosphorylation in the activation loop by phosphoinositide-dependent kinase-1 (PDK-1) is required for initial catalytic activity of PRKCZ . This is considered the primary activation event.

• Functional regulation: Thr560 phosphorylation represents a secondary regulatory mechanism that may modulate substrate specificity or subcellular localization rather than basic catalytic activity.

• Pathway specificity: Research indicates different upstream regulators for these phosphorylation events. While Thr410 phosphorylation is primarily regulated by PI3K signaling, Thr560 phosphorylation may respond to different upstream signals.

• Temporal dynamics: In experimental designs tracking PRKCZ activation kinetics, monitoring both phosphorylation sites can reveal the sequence and timing of activation events.

• Inhibitor responses: Different phosphorylation sites may show varied responses to PKC inhibitors, providing a more nuanced understanding of drug effects and mechanism of action.

How can Phospho-PRKCZ (Thr560) antibody be applied in cancer research models?

Phospho-PRKCZ (Thr560) antibody serves as a valuable tool in cancer research through several methodological approaches:

• Tissue microarray analysis: Researchers have used phospho-specific antibodies to analyze activation patterns across multiple tumor samples simultaneously. Similar to the approach with phospho-Akt antibodies in prostate cancer research , Phospho-PRKCZ (Thr560) antibody can be applied to investigate correlations between PRKCZ activation and tumor grade or stage.

• Metabolic fingerprinting: Recent research has linked PKCζ activity with enhanced arachidonic acid production in cancer cells harboring oncogenic PIK3CA mutations. Phospho-PRKCZ (Thr560) antibody can be used to correlate PKCζ activation state with metabolic alterations in cancer cells .

• Drug resistance mechanisms: By tracking changes in PRKCZ phosphorylation following treatment with chemotherapeutic agents, researchers can investigate the role of this kinase in acquired drug resistance.

• Cancer stem cell biology: Given PRKCZ's role in cell polarity and asymmetric division, the phospho-specific antibody can be employed to examine activation patterns in cancer stem cell populations versus bulk tumor cells.

What are common sources of non-specific signals when using Phospho-PRKCZ (Thr560) antibody?

Researchers should be aware of several potential sources of non-specific signals:

• Cross-reactivity with other PKC isoforms: Due to sequence homology among PKC family members, antibodies may recognize phosphorylated residues in other isoforms. Validation using knockout samples is critical to confirm specificity .

• Blocking conditions in Western blotting: When using phospho-specific antibodies, blocking with BSA (5%) rather than milk is recommended, as milk contains phosphoproteins that may interfere with detection .

• Dephosphorylation during sample preparation: Inadequate inhibition of phosphatases during sample preparation can lead to false negative results. Always include fresh phosphatase inhibitors in lysis buffers.

• Fixation artifacts in IHC: Overfixation can mask epitopes. Optimization of antigen retrieval methods is crucial for IHC applications of phospho-specific antibodies.

• Background in IF applications: For immunofluorescence, longer blocking times (2+ hours) and inclusion of normal serum from the species of the secondary antibody can help reduce non-specific binding.

How should researchers interpret conflicting data between phosphorylation status and functional outcomes?

When faced with discrepancies between PRKCZ phosphorylation status and expected functional outcomes:

• Consider multiple phosphorylation sites: As PRKCZ activity is regulated by phosphorylation at multiple sites, assess the phosphorylation status at both Thr410 and Thr560 to obtain a complete picture of activation .

• Examine protein-protein interactions: PRKCZ function depends not only on phosphorylation but also on interactions with scaffold proteins and substrates. Co-immunoprecipitation studies can reveal whether these interactions are intact despite phosphorylation.

• Assess subcellular localization: Proper function requires correct subcellular targeting. Use fractionation or immunofluorescence to determine if phosphorylated PRKCZ is correctly localized.

• Validate with functional assays: Complement phosphorylation data with direct measurements of PRKCZ catalytic activity using substrate phosphorylation assays.

• Consider compensatory mechanisms: In knockout models, other PKC isoforms may compensate for PRKCZ loss. For example, research with Prkcz -/- mice showed no learning and memory deficits despite previous evidence suggesting PRKCZ's importance in these processes .

What approaches can resolve detection issues in tissues with low PRKCZ expression?

For tissues with low endogenous PRKCZ expression, consider these methodological refinements:

• Signal amplification systems: Employ tyramide signal amplification (TSA) or similar technologies to enhance detection sensitivity in IHC and IF applications.

• Sample enrichment: For biochemical analyses, consider using phospho-protein enrichment techniques prior to Western blotting to concentrate the phosphorylated protein fraction.

• Alternative detection methods: More sensitive detection methods like proximity ligation assay (PLA) can detect low abundance phospho-proteins by generating amplifiable DNA signals when two antibodies bind in close proximity.

• Optimized extraction methods: Different tissue types may require adjusted extraction protocols to efficiently solubilize membrane-associated proteins like PRKCZ.

• Induced expression models: In experimental systems, consider using inducible expression systems to temporarily increase PRKCZ levels for mechanism studies.

How does Phospho-PRKCZ (Thr560) contribute to understanding neuronal learning and memory mechanisms?

Research using Phospho-PRKCZ (Thr560) antibodies has provided important insights into learning and memory mechanisms:

What role does PRKCZ Thr560 phosphorylation play in immune cell signaling and inflammation?

The role of PRKCZ Thr560 phosphorylation in immune function can be investigated using several approaches:

• T-cell activation studies: PRKCZ is essential for T-cell receptor (TCR)-mediated T-cell activation and links the TCR signaling complex to NF-kappa-B activation . Researchers can use Phospho-PRKCZ (Thr560) antibody to track activation kinetics during immune responses.

• Cytokine production: As PRKCZ is required for interleukin-2 (IL2) production , phosphorylation at Thr560 may serve as a biomarker for specific immune activation states.

• Inflammatory signaling: By correlating Thr560 phosphorylation with inflammatory mediator production, researchers can establish the significance of this modification in inflammatory diseases.

• Potential therapeutic targeting: Understanding the specific role of Thr560 phosphorylation could inform the development of selective inhibitors that target specific PKC functions without broadly inhibiting all PKC activities.

How can quantitative phosphoproteomics complement antibody-based detection of PRKCZ Thr560 phosphorylation?

Integration of antibody-based techniques with phosphoproteomics offers several advantages:

• Site-specific phosphorylation stoichiometry: While antibodies provide information about the presence of phosphorylation, mass spectrometry-based approaches can quantify the proportion of PRKCZ molecules phosphorylated at Thr560 versus unphosphorylated forms.

• Multi-site phosphorylation patterns: Phosphoproteomics can simultaneously detect multiple phosphorylation sites on PRKCZ, providing a comprehensive view of its activation state that cannot be achieved with single site-specific antibodies.

• Novel phosphorylation sites: Untargeted phosphoproteomics approaches can identify previously uncharacterized phosphorylation sites on PRKCZ that may have functional significance.

• Validation strategy: Researchers can use phosphoproteomics to validate antibody specificity by confirming the presence of the Thr560 phosphorylation in samples showing positive antibody staining.

• Pathway integration: Phosphoproteomics provides contextual information about the activation state of signaling networks in which PRKCZ operates, allowing for more comprehensive interpretation of Thr560 phosphorylation significance.